Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

Oragenics stock opened at $0.32 on Tuesday. The company’s 50 day simple moving average is $0.38 and its 200 day simple moving average is $1.03. Oragenics has a fifty-two week low of $0.28 and a fifty-two week high of $7.74. The firm has a market capitalization of $1.79 million, a price-to-earnings ratio of -0.05 and a beta of 0.49.

Institutional Trading of Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new position in shares of Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent reporting period. 18.71% of the stock is currently owned by institutional investors and hedge funds.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.